Cowen and Company’s PMV Pharmaceuticals PMVP Stock Holding History

Cowen and Company’s Portfolio PMVP Stock Details PMVP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1,261,529	Closed	-$26.3M	–	726
2022 Q1	$26.3M	Buy	+1,261,529	New	+$22.3M	2.53%	11

Other funds holding PMVP

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Cowen and Company's PMVP Position: Q2 2022 in Review

Cowen and Company sold out of PMV Pharmaceuticals (PMVP) in Q2 2022, closing a stake of 1,261,529 shares — an estimated $26.3M sold.

Cowen and Company first reported a position in PMVP in Q1 2022 and held it in 1 quarter. The position peaked at $26.3M in Q1 2022. 105 funds tracked by Wall St. Rank hold PMVP as of Q2 2022.

Cowen and Company reported no remaining PMV Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
Cowen and Company sold 1,261,529 PMV Pharmaceuticals shares in Q2 2022, an estimated $26.3M.
Cowen and Company first reported a position in PMV Pharmaceuticals in Q1 2022 and held it in 1 quarter.
Cowen and Company's PMV Pharmaceuticals position peaked at $26.3M in Q1 2022.
105 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q2 2022.

Based on Cowen and Company's 13F filing for Q2 2022, filed 5 Aug 2022.